A Month in Review: March's Top 5 Infectious Disease Stories

COVID-19 stories continue to be the most-read, but last month's top stories described how contracting COVID-19 increases the risk of gastrointestinal infection, C difficile infection, and cardiovascular disease.

Related Videos
Related Content

Vowst, Microbiota-Based Oral Therapeutic for Recurrent C diff Prevention, Is Now Available

June 5th 2023

Long COVID Lingers: Prolonged Symptoms and Recovery Patterns 2 Years After COVID-19

June 3rd 2023

The Rising Threat of Salmonella, Anticipated FDA Approvals, and More: The Week’s Top 5 Stories

May 19th 2023

Rising Threat: Evaluating Salmonella Treatment Options Amid Antimicrobial Resistance

May 15th 2023

Patient Perspectives on Rectal Administration for Recurrent C difficile Infection

May 15th 2023

Reduced Vancomycin Susceptibility in C difficile Leads to Worse Patient Outcomes

May 13th 2023

Vowst, Microbiota-Based Oral Therapeutic for Recurrent C diff Prevention, Is Now Available

June 5th 2023

Long COVID Lingers: Prolonged Symptoms and Recovery Patterns 2 Years After COVID-19

June 3rd 2023

The Rising Threat of Salmonella, Anticipated FDA Approvals, and More: The Week’s Top 5 Stories

May 19th 2023

Rising Threat: Evaluating Salmonella Treatment Options Amid Antimicrobial Resistance

May 15th 2023

Patient Perspectives on Rectal Administration for Recurrent C difficile Infection

May 15th 2023

Reduced Vancomycin Susceptibility in C difficile Leads to Worse Patient Outcomes

May 13th 2023

Vowst, Microbiota-Based Oral Therapeutic for Recurrent C diff Prevention, Is Now Available

June 5th 2023

Long COVID Lingers: Prolonged Symptoms and Recovery Patterns 2 Years After COVID-19

June 3rd 2023

The Rising Threat of Salmonella, Anticipated FDA Approvals, and More: The Week’s Top 5 Stories

May 19th 2023

Rising Threat: Evaluating Salmonella Treatment Options Amid Antimicrobial Resistance

May 15th 2023

Patient Perspectives on Rectal Administration for Recurrent C difficile Infection

May 15th 2023

Reduced Vancomycin Susceptibility in C difficile Leads to Worse Patient Outcomes

May 13th 2023
© 2023 MJH Life Sciences

All rights reserved.